These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6228938)

  • 21. A dose-response study with dihydroergotoxine mesylate in cerebrovascular disturbances.
    Yoshikawa M; Hirai S; Aizawa T; Kuroiwa Y; Goto F; Sofue I; Toyokura Y; Yamamura H; Iwasaki Y
    J Am Geriatr Soc; 1983 Jan; 31(1):1-7. PubMed ID: 6336765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double-blind placebo-controlled clinical trial in elderly patients.
    Rousseau JJ
    Clin Ther; 1987; 9(3):267-72. PubMed ID: 3111702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Therapy of chronic cerebrovascular insufficiency. Controlled comparative study of 2 cerebral antihypoxidosis agents].
    Szobor A; Klein M; Bräuer H
    MMW Munch Med Wochenschr; 1982 Oct; 124(41):897-900. PubMed ID: 6815511
    [No Abstract]   [Full Text] [Related]  

  • 24. [Clinical trials with dihydroergocristine in patients with vascular and cerebral insufficiency].
    Ingelmo M; Vivancos J; Peri J; Balcells Gorina A
    Rev Clin Esp; 1980 Dec; 159(6):399-402. PubMed ID: 6784197
    [No Abstract]   [Full Text] [Related]  

  • 25. [Treatment of chronic cerebrovascular insufficiency: comparison of nimodipine and dihydroergotoxine].
    Cosmi F; Caresia L; Panebianco G
    Clin Ter; 1986 Feb; 116(3):213-20. PubMed ID: 3698528
    [No Abstract]   [Full Text] [Related]  

  • 26. Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. Preliminary report.
    Yesavage JA; Hollister LE; Burian E
    J Am Geriatr Soc; 1979 Feb; 27(2):80-2. PubMed ID: 762369
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dihydroergocryptine in the management of senile psycho-organic syndrome.
    Scarzella L; Bono G; Bergamasco B
    Int J Clin Pharmacol Res; 1992; 12(1):37-46. PubMed ID: 1526697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Dihydroergocristine in organic brain psychosyndrome. Multicenter placebo-controlled clinical double-blind study in 240 patients].
    Lazzaroni M; Cattalini C; Massetto N; Poli A
    Arzneimittelforschung; 1992 Nov; 42(11A):1410-3. PubMed ID: 1492864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison of dihydroergotoxine and placebo in the treatment of moderate arterial hypertension in older persons].
    Bagatin J; Rumboldt Z; Jurisić M; Vujić D
    Med Pregl; 1988; 41(1-2):74-7. PubMed ID: 3054457
    [No Abstract]   [Full Text] [Related]  

  • 30. [One-year therapy with dihydroergocristine for treatment of impaired alertness and memory in elderly patients. Placebo-controlled multicenter study].
    Agliati G; Lazzaroni M; Mariani G; Marras F; Massetto N; Menozzi C; Ortenzi E; Perna G; Puppo N; Santambrogio S
    Arzneimittelforschung; 1992 Nov; 42(11A):1414-6. PubMed ID: 1492865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical assessment of brain failure in the elderly.
    McConnachie RW
    Pharmacology; 1978; 16 Suppl 1():27-35. PubMed ID: 347464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A long-term study with co-dergocrine mesylate (Hydergine) in healthy pensioners. Results after 3 years.
    Köberle S; Spiegel R
    Gerontology; 1984; 30 Suppl 1():3-52. PubMed ID: 6489764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ergoloid mesylates ('Hydergine') in the treatment of mental deterioration in the elderly: a 6-month double-blind, placebo-controlled trial.
    Rouy JM; Douillon AM; Compan B; Wolmark Y
    Curr Med Res Opin; 1989; 11(6):380-9. PubMed ID: 2651014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of cerebrovascular insufficiency].
    Cosentino F; Baldassarri R
    Clin Ter; 1979 Mar; 88(6):631-8. PubMed ID: 380878
    [No Abstract]   [Full Text] [Related]  

  • 35. A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.
    Balestreri R; Fontana L; Astengo F
    J Am Geriatr Soc; 1987 May; 35(5):425-30. PubMed ID: 3553281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DH Ergotoxin (Spofa) sublingual tablets in the treatment of cerebrovascular insufficiency in involution: clinical and experimental psychologic study.
    Misurec J; Morávek Z; Náhunek K; Cesková E; Sláma B; Svestka J
    Act Nerv Super (Praha); 1978 Dec; 20(4):266-7. PubMed ID: 367038
    [No Abstract]   [Full Text] [Related]  

  • 37. A double-blind evaluation of 'Hydergine' and placebo in the treatment of patients with organic brain syndrome and cerebral arteriosclerosis in a nursing home.
    Thibault A
    Curr Med Res Opin; 1974; 2(8):482-7. PubMed ID: 4217240
    [No Abstract]   [Full Text] [Related]  

  • 38. [Card-Hydergin for treatment of heart insufficiency in elderly patients with cerebrovascular deficiency].
    Schmidt W
    ZFA (Stuttgart); 1977 Mar; 53(8):447-52. PubMed ID: 324165
    [No Abstract]   [Full Text] [Related]  

  • 39. [A double-blind controlled clinical study on the use of mucopolysaccharides in the treatment of patients with cerebral vasculopathy. Comparison with a placebo].
    Bardin P; Campo R
    Clin Ter; 1987 Jan; 120(2):111-8. PubMed ID: 2972439
    [No Abstract]   [Full Text] [Related]  

  • 40. A controlled double-blind study of high-dose dihydroergotoxine mesylate (Hydergine) in mild dementia.
    Thienhaus OJ; Wheeler BG; Simon S; Zemlan FP; Hartford JT
    J Am Geriatr Soc; 1987 Mar; 35(3):219-23. PubMed ID: 3819261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.